Excellent R01 opportunity for early-stage investors to research HIV/AIDS and for genetic/epigenetic studies. The deadline to apply is October 19, 2022.
PeerJ is an O'Reiley Media Inc./Sage Publications Journal with an impact factor of 2.984 (2020). You can even publish for free provided your institution has a PeerJ Publishing Partnership.
CRISPR/Cas9 is a powerful gene-editing tool. In this paper, the authors used it to induce Alzheimer's in mice to create an Alzheimer's disease model and to screen for pathogenic gene targets. Traditionally, Alzheimer's models are based on the transgenic expression of human APP.
CRISPR/Cas9 is a great tool that will potentially help millions of people. Its use for treating liver diseases is promising especially for metabolic and acquired liver disorders.
According to this paper, low plasma GGT levels are associated with Inflammatory Bowel Disease (IBD). Several other diseases are related to polymorphism of the GGT gene.
Great opportunity for new investigators to work on pediatrics, maternal health by Purdue and Wisconsin university. Trainees can apply too as co-investigators as long as there is a principal investigator who qualifies.
Protein microarray are very effective in studying protein-protein interactions, protein-small molecule interactions. Their low cost and longer shelf-life makes them even more desirable option for studying protein chemistry.
This article answers an important pandemic question. Positivity on RT-PCR does not necessarily imply infectivity. Infectivity depends on a person's viral load. Viral culture results indicated positivity during peak viral load and tested negative 8 days after infection even though the RT-PCR was still positive.
This research paper discusses a novel approach that combines NASBA with microarray technology to test for specific pathogens in a variety of possible targets. The authors evaluated two different aaUTP salts to find out that the optimal concentration at 2mM resulted in the highest sensitivity.
Funding